ZA974223B - Biphenylsulfonamide matrix metalloproteinase inhibitors. - Google Patents
Biphenylsulfonamide matrix metalloproteinase inhibitors.Info
- Publication number
- ZA974223B ZA974223B ZA9704223A ZA974223A ZA974223B ZA 974223 B ZA974223 B ZA 974223B ZA 9704223 A ZA9704223 A ZA 9704223A ZA 974223 A ZA974223 A ZA 974223A ZA 974223 B ZA974223 B ZA 974223B
- Authority
- ZA
- South Africa
- Prior art keywords
- matrix metalloproteinase
- metalloproteinase inhibitors
- alkyl
- biphenylsulfonamide
- biphenylsulfonamide matrix
- Prior art date
Links
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- -1 nitro, amino Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1746096P | 1996-05-17 | 1996-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA974223B true ZA974223B (en) | 1997-12-10 |
Family
ID=21782716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9704223A ZA974223B (en) | 1996-05-17 | 1997-05-15 | Biphenylsulfonamide matrix metalloproteinase inhibitors. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0901466B1 (enExample) |
| JP (1) | JP2000511175A (enExample) |
| KR (1) | KR20000011095A (enExample) |
| CN (1) | CN1077885C (enExample) |
| AT (1) | ATE207891T1 (enExample) |
| BG (1) | BG63940B1 (enExample) |
| BR (1) | BR9710841A (enExample) |
| CA (1) | CA2253342A1 (enExample) |
| CZ (1) | CZ294063B6 (enExample) |
| DE (1) | DE69707865T2 (enExample) |
| DK (1) | DK0901466T3 (enExample) |
| EA (1) | EA001561B1 (enExample) |
| EE (1) | EE03965B1 (enExample) |
| ES (1) | ES2167733T3 (enExample) |
| IL (1) | IL126832A0 (enExample) |
| NO (1) | NO312510B1 (enExample) |
| NZ (1) | NZ332711A (enExample) |
| PL (1) | PL186416B1 (enExample) |
| PT (1) | PT901466E (enExample) |
| SK (1) | SK282863B6 (enExample) |
| WO (1) | WO1997044315A1 (enExample) |
| ZA (1) | ZA974223B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0766665B1 (en) * | 1994-06-22 | 1999-07-28 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US6124333A (en) * | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| WO1998025597A2 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| JP2001507342A (ja) | 1996-12-17 | 2001-06-05 | ワーナー−ランバート・コンパニー | 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用 |
| SI0946166T1 (en) * | 1996-12-17 | 2004-06-30 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for promoting wound healing |
| GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| PL338235A1 (en) | 1997-07-22 | 2000-10-09 | Shionogi & Co | Preparation for treating or preventing glomerulopathic states |
| AU751701B2 (en) * | 1997-12-23 | 2002-08-22 | Warner-Lambert Company | Ace inhibitor-MMP inhibitor combinations |
| US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| IL137465A0 (en) * | 1998-02-04 | 2001-07-24 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| NZ505994A (en) * | 1998-03-17 | 2003-10-31 | Warner Lambert Co | Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases |
| EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
| DE59903329D1 (en) * | 1998-07-16 | 2002-12-12 | Aventis Pharma Gmbh | Phosphin- und phosphonsäurederivate als arzneimittel |
| CA2335062A1 (en) * | 1998-07-21 | 2000-02-03 | Thomas Michael Andrew Bocan | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| DE19851184A1 (de) * | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| PL351374A1 (en) * | 1999-04-19 | 2003-04-07 | Shionogi & Co | Sulfonamide derivatives having oxadiazole rings |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| JP3910446B2 (ja) | 1999-11-26 | 2007-04-25 | 塩野義製薬株式会社 | Ｎｐｙｙ５拮抗剤 |
| CA2423885A1 (en) * | 2000-09-29 | 2003-03-27 | Shionogi & Co., Ltd. | Thiazole and oxazole derivatives |
| GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| JP4219810B2 (ja) * | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Ｍｍｐ阻害作用を有するスルホンアミド誘導体 |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| JP2007525406A (ja) * | 2003-12-04 | 2007-09-06 | ワイス | ビアリールスルホンアミドおよびその使用方法 |
| US8129406B2 (en) * | 2004-03-22 | 2012-03-06 | Southern Research Institute | Nonpeptide inhibitors of matrix metalloproteinases |
| CN101279956B (zh) * | 2008-04-25 | 2011-06-15 | 南昌大学 | 一种基质金属蛋白酶抑制剂及合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| EP0766665B1 (en) * | 1994-06-22 | 1999-07-28 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1997
- 1997-04-24 CN CN97194719A patent/CN1077885C/zh not_active Expired - Fee Related
- 1997-04-24 ES ES97918788T patent/ES2167733T3/es not_active Expired - Lifetime
- 1997-04-24 JP JP09542377A patent/JP2000511175A/ja not_active Abandoned
- 1997-04-24 DE DE69707865T patent/DE69707865T2/de not_active Expired - Fee Related
- 1997-04-24 BR BR9710841A patent/BR9710841A/pt not_active IP Right Cessation
- 1997-04-24 CA CA002253342A patent/CA2253342A1/en not_active Abandoned
- 1997-04-24 SK SK1577-98A patent/SK282863B6/sk unknown
- 1997-04-24 EP EP97918788A patent/EP0901466B1/en not_active Expired - Lifetime
- 1997-04-24 CZ CZ19983668A patent/CZ294063B6/cs not_active IP Right Cessation
- 1997-04-24 EA EA199800988A patent/EA001561B1/ru not_active IP Right Cessation
- 1997-04-24 WO PCT/US1997/006801 patent/WO1997044315A1/en not_active Ceased
- 1997-04-24 PT PT97918788T patent/PT901466E/pt unknown
- 1997-04-24 IL IL12683297A patent/IL126832A0/xx unknown
- 1997-04-24 KR KR1019980709253A patent/KR20000011095A/ko not_active Ceased
- 1997-04-24 DK DK97918788T patent/DK0901466T3/da active
- 1997-04-24 NZ NZ332711A patent/NZ332711A/en unknown
- 1997-04-24 PL PL97329929A patent/PL186416B1/pl not_active IP Right Cessation
- 1997-04-24 EE EE9800397A patent/EE03965B1/xx not_active IP Right Cessation
- 1997-04-24 AT AT97918788T patent/ATE207891T1/de not_active IP Right Cessation
- 1997-05-15 ZA ZA9704223A patent/ZA974223B/xx unknown
-
1998
- 1998-11-12 BG BG102918A patent/BG63940B1/bg unknown
- 1998-11-16 NO NO19985326A patent/NO312510B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1077885C (zh) | 2002-01-16 |
| BR9710841A (pt) | 1999-08-17 |
| PL329929A1 (en) | 1999-04-26 |
| JP2000511175A (ja) | 2000-08-29 |
| WO1997044315A1 (en) | 1997-11-27 |
| DK0901466T3 (da) | 2002-02-18 |
| SK282863B6 (sk) | 2002-12-03 |
| DE69707865T2 (de) | 2002-05-02 |
| PL186416B1 (pl) | 2004-01-30 |
| CA2253342A1 (en) | 1997-11-27 |
| EP0901466B1 (en) | 2001-10-31 |
| BG102918A (en) | 1999-09-30 |
| NZ332711A (en) | 2000-06-23 |
| NO312510B1 (no) | 2002-05-21 |
| KR20000011095A (ko) | 2000-02-25 |
| BG63940B1 (bg) | 2003-07-31 |
| PT901466E (pt) | 2002-04-29 |
| ATE207891T1 (de) | 2001-11-15 |
| IL126832A0 (en) | 1999-08-17 |
| CN1219166A (zh) | 1999-06-09 |
| AU2680397A (en) | 1997-12-09 |
| SK157798A3 (en) | 1999-04-13 |
| NO985326L (no) | 1999-01-14 |
| DE69707865D1 (de) | 2001-12-06 |
| EA199800988A1 (ru) | 1999-04-29 |
| ES2167733T3 (es) | 2002-05-16 |
| AU713286B2 (en) | 1999-11-25 |
| HK1019585A1 (en) | 2000-02-18 |
| EE9800397A (et) | 1999-06-15 |
| CZ366898A3 (cs) | 1999-02-17 |
| CZ294063B6 (cs) | 2004-09-15 |
| EA001561B1 (ru) | 2001-04-23 |
| EE03965B1 (et) | 2003-02-17 |
| NO985326D0 (no) | 1998-11-16 |
| EP0901466A1 (en) | 1999-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA974223B (en) | Biphenylsulfonamide matrix metalloproteinase inhibitors. | |
| AU6894800A (en) | Caspase inhibitors and uses thereof | |
| WO2003024448A3 (en) | Inhibitors of histone deacetylase | |
| NZ332762A (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| IL128900A0 (en) | Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor | |
| AU2001248701A1 (en) | Inhibitors of histone deacetylase | |
| PL312196A1 (en) | Heterocyclic phenyl compounds as inhibitors of cyclooxygenase-2 | |
| AU2483000A (en) | Treatment of asthma with mek inhibitors | |
| IL141410A0 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) | |
| AU4284196A (en) | Substituted biphenyl compounds for the treatment of inflammation | |
| NZ285846A (en) | Arylsulphonamido-substituted hydroxamic acids and preparation and medicaments useful for inhibiting metalloproteinases | |
| NZ333550A (en) | Matrix metalloproteinase inhibitors for inhibiting the release of TNF | |
| AU1314300A (en) | Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons | |
| CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
| AU9066498A (en) | Substituted 6-alkylphenanthridines | |
| AU2001255646A1 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | |
| DE69736945D1 (de) | Biphenylverbindungen sowie ihre anwendung als östrogene mittel | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| GR3032698T3 (en) | Organic compounds | |
| AU3729397A (en) | Butyric acid matrix metalloproteinase inhibitors | |
| BR9906803A (pt) | Processo para tratamento de copd | |
| ZA982808B (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia |